5784-66-7

Basic information

• Product Name: 3-[3,5-bis(trifluoromethyl)phenyl]-6,8-dichloro-2-methylquinazolin-4(3H)-one
• Synonyms: 4(3H)-quinazolinone, 3-[3,5-bis(trifluoromethyl)phenyl]-6,8-dichloro-2-methyl-
• CAS NO: 5784-66-7
• Molecular Formula: C₁₈H₁₈O₆
• Molecular Weight: 441.1546
• Mol File: 5784-66-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 471.2°C at 760 mmHg
• Flash Point: 238.8°C
• Density: 1.57g/cm³
• Vapor Pressure: 4.74E-09mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 3-[3,5-bis(trifluoromethyl)phenyl]-6,8-dichloro-2-methylquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[3,5-bis(trifluoromethyl)phenyl]-6,8-dichloro-2-methylquinazolin-4(3H)-one(5784-66-7)
• EPA Substance Registry System: 3-[3,5-bis(trifluoromethyl)phenyl]-6,8-dichloro-2-methylquinazolin-4(3H)-one(5784-66-7)

Safety Data

• Hazardous Substances Data: 5784-66-7(Hazardous Substances Data)

Upstream product

• 6315-52-2 1,2-bis-tosyloxyethane 
• 121-33-5 vanillin 
• 107-06-2 1,2-dichloro-ethane 
• 106-93-4 ethylene dibromide 
• 99070-23-2 4-(2-bromo-ethoxy)-3-methoxy-benzaldehyde 

Downstream Products

• 98688-18-7 1,2-bis(4-hydroxymethyl-2-methoxyphenoxy)ethane 
• 103331-08-4 1,2-bis-(4-hexylaminomethyl-2-methoxy-phenoxy)-ethane 

Relevant articles and documents

Microwave assisted synthesis, characterization and biochemical study of new chalcones

A number of new chalcones were prepared from 1,2-bis(2-methoxy-4-vinylphenoxy) ethane by Claisen-Schmidt condensation using a microwave as a heat source, which has beneficial effect on many important aspects such as reducing reaction time, lowering the so

Targeting receptor tyrosine kinase VEGFR-2 in hepatocellular cancer: Rational design, synthesis and biological evaluation of 1,2-disubstituted benzimidazoles

In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is twofold; it aimed first at studying the effect of replacing the 5-methylfuryl moiety of the well-known antiangiogenic 2-furylbenzimidazoles with an isopropyl moiety on the VEGFR-2 inhibitory activity and the cytotoxic activity. Our second objective was to further optimize the structures of the benzimidazole derivatives through elongation of the side chains at their one-position for the design of more potent type II-like VEGFR-2 inhibitors. The designed 1,2-disubstituted benzimidazoles demonstrated potent cytotoxic activity against the HepG2 cell line, reaching IC50 = 1.98 μM in comparison to sorafenib (IC50 = 10.99 μM). In addition, the synthesized compounds revealed promising VEGFR-2 inhibitory activity in the HepG2 cell line, e.g., compounds 17a and 6 showed 82% and 80% inhibition, respectively, in comparison to sorafenib (% inhibition = 92%). Studying the effect of 17a on the HepG2 cell cycle demonstrated that 17a arrested the cell cycle at the G2/M phase and induced a dose-dependent apoptotic effect. Molecular docking studies of the synthesized 1,2-disubstituted benzimidazoles in the VEGFR-2 active site displayed their ability to accomplish the essential hydrogen bonding and hydrophobic interactions for optimum inhibitory activity.

Efficient synthesis of alkylene bridging bisdihydropyridines

Under microwave irradiation, vanillin was alkylated with α,W-dihaloalkane to give 4,4'-alkylene-bridging vanillins, which in turn underwent one-pot multicomponent reactions with excess of ethyl acetoacetate and ammonium bicarbonate to give 4,4'-alkoxy-bri